Your Pitch Isn’t Broken. Your Business Model Is.
What a Harvard professor, an AI engineer, and a very uncomfortable VC meeting taught me about bioconvergence startups
A seasoned physician. Former Harvard faculty. Decades of clinical insight into how healthcare systems actually work, not in theory, but in the messy, bureaucratic, beautifully dysfunctional reality of it.His co-founder: a sharp AI engineer who could make algorithms do things most people can’t explain, let alone build. Together, they had developed something genuinely valuable. A bioconvergence solution with real potential to reduce costs and improve outcomes at a national healthcare system level.They came to me frustrated. VC meetings weren’t converting. Investors were nodding politely and going quiet. You know that specific kind of quiet that means “we’ll be in touch” but actually means “we won’t.””They don’t understand our technology,” they told me. That wasn’t the problem.The real problem had three words: Who is the customer? In bioconvergence, this question is deceptively hard. You’re sitting at the intersection of biology, engineering, and AI, which means your technology can theoretically serve hospitals, pharma companies, insurance providers, governments, and research institutions. All at once. All legitimately. That’s not a strength in a pitch. That’s a red flag dressed in a lab coat. Here’s what I see repeatedly with bioconvergence founders, especially the brilliant ones. They’re so deep in the science, so convinced of the technology’s merit (rightfully so), that they skip the most fundamental business question: who is handing you a check, and why, and when?In this case, the value was genuinely systemic. The solution could save a national health system millions. But “national health systems” don’t have a procurement officer you can call on Monday morning. They have ministries, tenders, multi-year budget cycles, and political considerations that have absolutely nothing to do with how elegant your algorithm is. So when a VC asked “what’s your go-to-market?”, the founders answered with impact metrics. When the VC asked “who’s your first paying customer?”, they answered with vision.Vision is not a business model. It’s a prerequisite for one.The fix wasn’t the pitch. It was the thinking behind it. We went back to basics. The kind of basics that feel almost embarrassingly simple when you’re a Harvard-trained physician and a machine learning engineer. But simple isn’t the same as obvious, and obvious isn’t the same as done.Three questions. That’s all it took to reshape everything: – Who feels the pain most acutely, and has a budget to solve it? Not who should care. Who does care, today, enough to actually move money. – What does success look like for them in 12 months? Not in five years. Not at scale. Next year. What changes in their world? – Can we build a model where they pay us before we’ve proven everything? A pilot. A data-sharing agreement. A consulting retainer that funds early validation. Something that turns “we believe in this” into “here’s a wire transfer.”The answers reshaped the pitch, the roadmap, and the funding ask. The investors started leaning forward instead of going quiet.
Why this matters specifically in bioconvergence Bioconvergence startups face a unique trap. The technology is multidisciplinary by nature, which means the value is also multidisciplinary. You genuinely can serve multiple stakeholders. The problem is that “we can serve everyone” is what you say when you haven’t decided to serve anyone. Investors at pre-seed and seed stage are not buying your full potential. They’re buying your clarity of thought. They want to see that you’ve made hard choices. That you’ve narrowed the infinite into the specific. That you can sit across from a skeptical person with a checkbook and say, with complete confidence: this is our customer, this is their problem, this is how we get paid. The global bioconvergence market is projected to reach $371 billion by 2035. That’s a genuinely exciting number. But in a room with a VC, that number is wallpaper. It’s background. What cuts through is the specific answer to a simple question: so who’s your first customer? The thing nobody tells brilliant founders The startups that raise are not always the ones with the best technology. They’re often the ones who can tell the clearest story about a specific person, with a specific problem, who will pay a specific amount, by a specific date.In bioconvergence, that clarity is harder to achieve. The science is complex, the regulatory pathway is long, and the stakeholder map looks like someone spilled spaghetti on a whiteboard. That’s exactly why investors reward it so heavily when they actually see it. Your technology might be breakthrough. Your team might be exceptional. But if you walk into a VC meeting without knowing who your customer is, you’re not ready to raise. You’re ready to keep building. There’s a difference. Know which room you’re in.
I work with deep-tech and bioconvergence founders on investor strategy and business planning. If this resonated, I’d love to hear what challenge you’re navigating right now.
